Who is affected by this change?

This affects Independence Blue Cross Neurology, Oncology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Oct 1, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.015e, Alemtuzumab (Lemtrada®)

Independence Blue Cross·Neurology, Oncology·Pharmacy

Effective date

Oct 1, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.015e for Alemtuzumab (Lemtrada®) has been updated effective October 1, 2025. This is a pharmacy-related policy change that may affect coverage criteria, prior authorization requirements, or billing procedures for this multiple sclerosis medication.

Action Required

Action needed

Effective October 1, 2025: Billing team should review the complete MA08.015e policy details for Alemtuzumab (Lemtrada®) to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for Medicare Advantage patients. Coordinate with pharmacy and clinical staff to ensure compliance with updated requirements.

Related policy hubs

Independence Blue Cross policies Neurology Oncology